Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wanlong Lin

Showing results (1-10 of 26) with videos related to

Pageof 3
Sort By:
Journal of Neurology|May 28, 2025
Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Andrology|October 27, 2024
Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 9, 2025
Association of oxidative balance score with hypertension in children and adolescents: NHANES 1999-2018Wen Wu, Xiaorong Su, Wei Zhuang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2023
Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System DatabaseXiuxian Lin, Jianhui Yang, Lizhu Weng, et al.
BMC Pharmacology & Toxicology|August 9, 2024
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance studyWanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 22, 2024
Randomized controlled trial of an app for cancer pain managementLizhu Weng, Wanlong Lin, Xiuxian Lin, et al.
Drugs - Real World Outcomes|April 16, 2025
Evaluation of the Association Between Postpartum Hemorrhage and Antidepressant Use: A Mendelian Randomization StudyZhenzhen Chen, Qingqing Lv, Shiteng Lin, et al.
Cancer Investigation|July 5, 2026
Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting SystemYongfeng Zhu, Yanbin Zeng, Wanlong Lin, et al.
BMC Infectious Diseases|May 9, 2024
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting systemYunsong Li, Xiaoling Wang, Yufang Liao, et al.
International Journal of Clinical Pharmacy|December 15, 2023
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting systemWanlong Lin, Jiabing Xu, Yufang Liao, et al.
Pageof 3

Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Journal of Neurology|May 28, 2025
Safety concerns of maternal antiseizure medications exposure on perinatal and offspring outcomes: a disproportionality analysis based on FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Andrology|October 27, 2024
Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting systemYanbin Zeng, Wanlong Lin, Wei Zhuang
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|September 9, 2025
Association of oxidative balance score with hypertension in children and adolescents: NHANES 1999-2018Wen Wu, Xiaorong Su, Wei Zhuang, et al.
The Journal of Allergy and Clinical Immunology. in Practice|February 3, 2023
Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System DatabaseXiuxian Lin, Jianhui Yang, Lizhu Weng, et al.
BMC Pharmacology & Toxicology|August 9, 2024
Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA's adverse event reporting system: a case control pharmacovigilance studyWanlong Lin, Yanbin Zeng, Lizhu Weng, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 22, 2024
Randomized controlled trial of an app for cancer pain managementLizhu Weng, Wanlong Lin, Xiuxian Lin, et al.
Drugs - Real World Outcomes|April 16, 2025
Evaluation of the Association Between Postpartum Hemorrhage and Antidepressant Use: A Mendelian Randomization StudyZhenzhen Chen, Qingqing Lv, Shiteng Lin, et al.
Cancer Investigation|July 5, 2026
Profiling Immune-Related Adverse Events Associated with Imatinib: A Two-Decade Real-World Safety Study Based on FDA Adverse Event Reporting SystemYongfeng Zhu, Yanbin Zeng, Wanlong Lin, et al.
BMC Infectious Diseases|May 9, 2024
Safety analysis of Oseltamivir and Baloxavir Marboxil after market approval: a pharmacovigilance study based on the FDA adverse event reporting systemYunsong Li, Xiaoling Wang, Yufang Liao, et al.
International Journal of Clinical Pharmacy|December 15, 2023
Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting systemWanlong Lin, Jiabing Xu, Yufang Liao, et al.
Pageof 3